Eukaryotic initiation factor: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 14: | Line 14: | ||
*<scene name='50/507723/Cv/4'>P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE (7-methyl GPPPA) binding site</scene>. Water molecules shown as red spheres. | *<scene name='50/507723/Cv/4'>P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE (7-methyl GPPPA) binding site</scene>. Water molecules shown as red spheres. | ||
==3D structures of eukaryotic initiation factor== | |||
[[Eukaryotic initiation factor 3D structures]] | |||
</StructureSection> | </StructureSection> | ||
==3D structures of eukaryotic initiation factor== | ==3D structures of eukaryotic initiation factor== | ||
| Line 33: | Line 36: | ||
**[[1kl9]], [[1q8k]], [[5oa9]] – hEIF2A subunit 1<BR /> | **[[1kl9]], [[1q8k]], [[5oa9]] – hEIF2A subunit 1<BR /> | ||
**[[1q8x]] – hEIF2A - NMR<BR /> | **[[1q8x]] – hEIF2A - NMR<BR /> | ||
**[[3ecs]] – hEIF2B<br /> | |||
**[[6ezo]] – hEIF2B + drug <br /> | **[[6ezo]] – hEIF2B + drug <br /> | ||
**[[6o9z]], [[6o85]], [[6o81]], [[6jlx]], [[6jlw]], [[6i7t]] – hEIF2B + hEIF2 – Cryo EM <br /> | |||
**[[5w2f]] – hEIF2D C-terminal <br /> | **[[5w2f]] – hEIF2D C-terminal <br /> | ||
**[[5oa3]] – hEIF2D in 40S ribosome – Cryo EM <br /> | **[[5oa3]] – hEIF2D in 40S ribosome – Cryo EM <br /> | ||
| Line 39: | Line 44: | ||
**[[3wj9]] - EIF2A – fission yeast<br /> | **[[3wj9]] - EIF2A – fission yeast<br /> | ||
**[[2a19]], [[2a1a]] – yEIF2A (mutant) + interferon-induced protein kinase<BR /> | **[[2a19]], [[2a1a]] – yEIF2A (mutant) + interferon-induced protein kinase<BR /> | ||
**[[6i3m]] – yEIF2B + yEIF2 – Cryo EM <br /> | |||
**[[4zgq]], [[4zgn]] – yEIF2G residues 410-527 + CDC123<br /> | **[[4zgq]], [[4zgn]] – yEIF2G residues 410-527 + CDC123<br /> | ||
**[[ | **[[3wj9]] - fyEIF2A – fission yeast<br /> | ||
**[[6jlz]], [[6jly]] - fyEIF2A + EIF2B<br /> | |||
*EIF2C or argonaute | *EIF2C or argonaute | ||
**[[5w6v]] – hEI2C1 + RNA + GW182<br /> | **[[5w6v]] – hEI2C1 + RNA + GW182<br /> | ||
**[[3luk]] – hEI2C2 mid domain<br /> | **[[3luk]] – hEI2C2 mid domain<br /> | ||
**[[3lud]], [[3lug]], [[3luh]], [[3luj]], [[3qx8]], [[3qx9]] - hEIF2C mid domain + nucleotide<br /> | **[[3lud]], [[3lug]], [[3luh]], [[3luj]], [[3qx8]], [[3qx9]] - hEIF2C mid domain + nucleotide<br /> | ||
**[[5t7b]], [[5ki6]], [[4f3t]] – hEI2C2 + RNA<br /> | **[[5t7b]], [[5ki6]], [[4f3t]], [[6ra4]] – hEI2C2 + RNA<br /> | ||
**[[4z4i]], [[4z4h]], [[4z4g]], [[4z4f]], [[4z4e]], [[4z4d]], [[4z4c]], [[4w5t]], [[4w5r]], [[4w5q]], [[4w5o]], [[4w5n]], [[4ola]], [[6cbd]], [[5wea]], [[5js2]], [[5js1]], [[4olb]] – hEI2C2 (mutant) + RNA<br /> | **[[4z4i]], [[4z4h]], [[4z4g]], [[4z4f]], [[4z4e]], [[4z4d]], [[4z4c]], [[4w5t]], [[4w5r]], [[4w5q]], [[4w5o]], [[4w5n]], [[4ola]], [[6cbd]], [[5wea]], [[5js2]], [[5js1]], [[4olb]], [[6n4o]] – hEI2C2 (mutant) + RNA<br /> | ||
**[[5vm9]] – hEI2C3 + RNA<br /> | **[[5vm9]] – hEI2C3 + RNA<br /> | ||
*EIF3 | *EIF3 | ||
**[[3j8b]], [[3j8c]] - hEIF3A + hEIF3C + hEIF3E + hEIF3F + hEIF3H + hEIF3K + hEIF3L + hEIF3M – cryo EM<br /> | |||
**[[5a5t]] - rEIF3A + rEIF3C + rEIF3E + rEIF3F + rEIF3H + rEIF3K + rEIF3M – Cryo EM - rat<br />**[[4kxt]], [[4krf]], [[4kre]], [[1si2]], [[1si3]] – hEI2C1 + RNA<br /> | |||
**[[4k51]], [[4u1d]] - yEIF3A PCI domain<br /> | **[[4k51]], [[4u1d]] - yEIF3A PCI domain<br /> | ||
**[[4u1c]] - yEIF3A PCI + yEIF3C PCI<br /> | |||
**[[2nlw]] - hEIF3B RNA recognition domain – NMR<BR /> | **[[2nlw]] - hEIF3B RNA recognition domain – NMR<BR /> | ||
**[[3ns5]], [[3ns6]] - yEIF3B RNA recognition domain<BR /> | **[[3ns5]], [[3ns6]] - yEIF3B RNA recognition domain<BR /> | ||
**[[4u1f]] - yEIF3B middle domain<br /> | **[[4u1f]] - yEIF3B middle domain<br /> | ||
| Line 61: | Line 71: | ||
**[[2krb]] - hEIF3B RNA recognition domain + hEIF3J peptide<br /> | **[[2krb]] - hEIF3B RNA recognition domain + hEIF3J peptide<br /> | ||
**[[5k1h]] – hEIF3B + EIF3A C-terminal<br /> | **[[5k1h]] – hEIF3B + EIF3A C-terminal<br /> | ||
**[[5krb]], [[5krc]], [[5krd]], [[5k4d]], [[5k4c]], [[5k4b]] – EIF3D – wasp<br /> | **[[5krb]], [[5krc]], [[5krd]], [[5k4d]], [[5k4c]], [[5k4b]] – EIF3D – wasp<br /> | ||
**[[2cq0]] – hEIF3G RNA recognition domain – NMR<BR /> | **[[2cq0]] – hEIF3G RNA recognition domain – NMR<BR /> | ||
| Line 70: | Line 79: | ||
**[[4u1e]] - yEIF3B CTD + yEIF3I + yEIF3G NTD<br /> | **[[4u1e]] - yEIF3B CTD + yEIF3I + yEIF3G NTD<br /> | ||
**[[5a5u]] - rEIF3B + rEIF3I – Cryo EM<br /> | **[[5a5u]] - rEIF3B + rEIF3I – Cryo EM<br /> | ||
**[[3bpj]] – hEIF3J<BR /> | **[[3bpj]] – hEIF3J<BR /> | ||
**[[1rz4]] – hEIF3K<br /> | **[[1rz4]] – hEIF3K<br /> | ||
**[[ | **[[4nox]] – CtEIF3B – ''Chaetomium thermophilum''<br /> | ||
*EIF4 | *EIF4 | ||
Revision as of 10:45, 24 June 2019
FunctionEukaryotic initiation factors (EIF) are involved in the initiation of protein translation. They form a complex with the small subunit of the ribosome and Met-tRNA which scans the mRNA and recognizes the initiation codon AUG[1]. For details on EIF4 see C-terminal portion of human eIF4GI. DiseaseOverexpression of individual subunits of eIF3 may cause malignant transformation [2]. Overexpression of eIF4g is implicated in breast cancer. Structural insightsEIF domains include the N terminal domain (NTD), C terminal domain (CTD), RNA recognition domain, middle domain, PAZ domain of EIF2C and a protein-protein interaction domain (PCI) of EIF3.
3D structures of eukaryotic initiation factorEukaryotic initiation factor 3D structures
|
| ||||||||||
3D structures of eukaryotic initiation factor3D structures of eukaryotic initiation factor
Updated on 24-June-2019
ReferencesReferences
- ↑ Jivotovskaya AV, Valasek L, Hinnebusch AG, Nielsen KH. Eukaryotic translation initiation factor 3 (eIF3) and eIF2 can promote mRNA binding to 40S subunits independently of eIF4G in yeast. Mol Cell Biol. 2006 Feb;26(4):1355-72. PMID:16449648 doi:http://dx.doi.org/10.1128/MCB.26.4.1355-1372.2006
- ↑ Hershey JW. The role of eIF3 and its individual subunits in cancer. Biochim Biophys Acta. 2015 Jul;1849(7):792-800. doi:, 10.1016/j.bbagrm.2014.10.005. Epub 2014 Nov 1. PMID:25450521 doi:http://dx.doi.org/10.1016/j.bbagrm.2014.10.005